Enovis Corporation (NYSE:ENOV) Stock Has Average Target Price of $39.50 According to Analysts

Shares of Enovis Corporation (NYSE:ENOV) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and ten have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $37.25.

ENOV has been the subject of several research analyst reports. Citizens Jmp cut their price objective on Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a report on Wednesday, September 2nd. Evercore set a $32.00 target price on Enovis in a report on Monday, July 6th. Canaccord Genuity Group lowered their target price on Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 17th. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, BTIG Research cut their price target on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, September 1st.

Enovis Trading Up 4.1%

NYSE:ENOV opened at $19.00 on Wednesday. The company has a market cap of $1.10 billion, a PE ratio of 5.45 and a beta of 1.37. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The company has a 50 day simple moving average of $21.25 and a two-hundred day simple moving average of $23.24. Enovis has a 12 month low of $16.70 and a 12 month high of $34.28.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The company’s revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.79 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis will post 3.15 earnings per share for the current year.

Insider Activity

In other Enovis news, CEO Damien Mcdonald acquired 13,035 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Oliver Engert bought 2,660 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were acquired at an average price of $18.80 per share, with a total value of $50,008.00. Following the completion of the transaction, the insider directly owned 63,898 shares of the company’s stock, valued at $1,201,282.40. This trade represents a 4.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 23,293 shares of company stock valued at $449,599 in the last ninety days. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

A number of institutional investors have recently bought and sold shares of the stock. Allworth Financial LP raised its stake in Enovis by 59.7% in the 2nd quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock worth $36,000 after acquiring an additional 652 shares during the last quarter. IFP Advisors Inc grew its stake in Enovis by 5,590.5% during the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares during the last quarter. Amundi grew its stake in Enovis by 2.3% during the 1st quarter. Amundi now owns 74,184 shares of the company’s stock valued at $1,688,000 after purchasing an additional 1,677 shares during the last quarter. Handelsbanken Fonder AB grew its stake in Enovis by 9.3% during the 2nd quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock valued at $437,000 after purchasing an additional 1,800 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Enovis during the 2nd quarter valued at about $39,000. 98.45% of the stock is owned by institutional investors.

About Enovis

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.